Could a blood pressure drug prevent kidney failure in liver patients?
NCT ID NCT07422948
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether starting midodrine early can help control ascites (fluid buildup in the belly) and prevent kidney problems in people with acute-on-chronic liver failure. About 113 participants will receive either midodrine plus standard care or standard care alone. The main goal is to see if more patients are free of ascites after 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
midodrine
What this could lead to
If it works, this could offer a new way to manage fluid buildup and reduce kidney complications in liver failure patients.
What could go wrong
This is a small, early-stage trial that hasn't started yet. Midodrine may not improve outcomes and could cause side effects like high blood pressure or skin reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE-ON-CHRONIC LIVER FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, 110070, India
Contact Phone: •••-•••-•••• Email: •••••@•••••